Treatment of a unique anemia in patients with IDDM with epoetin alfa.
Diabetes Care
; 21(3): 423-6, 1998 Mar.
Article
en En
| MEDLINE
| ID: mdl-9540026
ABSTRACT
OBJECTIVE:
To identify and treat a unique form of anemia in patients with long-term IDDM. RESEARCH DESIGN ANDMETHODS:
Patients with IDDM, unexplained symptomatic anemia, and serum creatinine levels of < 177 mumol/l (2.0 mg/dl) were treated with epoetin alfa (Procrit, Ortho Biotech, Raritan, NJ), 50 U/kg three times weekly, subcutaneously, to reach a target hematocrit of 38-40%. Baseline serum erythropoietin titers were measured before drug therapy.RESULTS:
Six patients were treated with epoetin alfa. Median age of the group was 74 years, with IDDM being diagnosed for a median of > 20 years. All patients had symptoms of anemia with a median hematocrit of 28.9% (range 27-31). Compared with iron deficiency control patients, the group had a limited erythropoietin (EPO) response to the degree of anemia. All patients showed increases in hematocrit, median peak of 40.9%, with median time-to-peak response of 12 weeks. Baseline symptoms of anemia resolved in all patients. No adverse effects were noted during the treatment period.CONCLUSIONS:
There is a unique form of anemia in patients with long-term IDDM and clinically normal renal function who respond to low-dose epoetin alfa therapy. The rapid response to therapy and depressed baseline erythropoietin titers suggest the anemia is due to a lack of endogenous EPO release.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Eritropoyetina
/
Diabetes Mellitus Tipo 1
/
Hematínicos
/
Anemia
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Diabetes Care
Año:
1998
Tipo del documento:
Article
País de afiliación:
Estados Unidos